Nature’s Sunshine Products (NASDAQ:NATR) EVP Nathan Brower Sells 3,800 Shares of Stock

Nature’s Sunshine Products, Inc. (NASDAQ:NATR) EVP Nathan Brower sold 3,800 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $20.81, for a total value of $79,078.00. Following the sale, the executive vice president owned 46,735 shares of the company’s stock, valued at $972,555.35. The trade was a 7.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Nature’s Sunshine Products Price Performance

NASDAQ NATR opened at $20.82 on Wednesday. The firm has a market capitalization of $364.27 million, a price-to-earnings ratio of 28.14 and a beta of 1.09. The company has a 50 day simple moving average of $15.92 and a 200-day simple moving average of $15.47. Nature’s Sunshine Products, Inc. has a 52-week low of $11.01 and a 52-week high of $21.64.

Nature’s Sunshine Products (NASDAQ:NATR) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.18. Nature’s Sunshine Products had a net margin of 3.06% and a return on equity of 10.19%. The firm had revenue of $88.99 million for the quarter, compared to analyst estimates of $119.39 million. Nature’s Sunshine Products has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. grew its position in shares of Nature’s Sunshine Products by 49.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 109,768 shares of the company’s stock valued at $1,704,000 after purchasing an additional 36,450 shares during the last quarter. NewEdge Advisors LLC grew its holdings in Nature’s Sunshine Products by 2,113.6% in the 3rd quarter. NewEdge Advisors LLC now owns 15,606 shares of the company’s stock valued at $242,000 after buying an additional 14,901 shares during the last quarter. Verition Fund Management LLC bought a new position in Nature’s Sunshine Products in the 3rd quarter worth approximately $210,000. Qube Research & Technologies Ltd boosted its position in shares of Nature’s Sunshine Products by 459.8% in the third quarter. Qube Research & Technologies Ltd now owns 66,454 shares of the company’s stock valued at $1,031,000 after acquiring an additional 54,582 shares during the period. Finally, Public Employees Retirement System of Ohio grew its stake in shares of Nature’s Sunshine Products by 76.9% in the third quarter. Public Employees Retirement System of Ohio now owns 10,791 shares of the company’s stock worth $167,000 after acquiring an additional 4,692 shares during the last quarter. Institutional investors and hedge funds own 79.40% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on NATR shares. DA Davidson raised their price objective on shares of Nature’s Sunshine Products from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Canaccord Genuity Group upped their price objective on shares of Nature’s Sunshine Products from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Nature’s Sunshine Products in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

About Nature’s Sunshine Products

Nature’s Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.